Nature’s Toolbox, Inc. (NTx), a Rio Rancho-based life sciences company, announced Tuesday that Marcel Roche has been appointed chief financial officer.

NTx, which facilites innovative RNA and protein research and manufacturing, said in a release that Roche “brings over 20 years of experience as a finance executive at both private and public life science and technology companies, including Illumina, Guardant Health, and Mission Bio.”

“I am thrilled to be joining a company that delivers a trifecta of seasoned leadership, highly differentiated technology, and multi-billion-dollar addressable markets,” Roche said. “NTx is uniquely positioned to revolutionize biomanufacturing by expanding access to life saving RNA and protein therapies. Additionally, NTx’s technology enables decentralized vaccine production, securing timely response to pandemics.”

During his tenure at Illumina, Roche deployed the global financial planning practice and systems, led the DNA sequencing cost accounting team and supported revenue growth from $70 million to more than $1 billion. While at Guardant Health, Roche successfully built out the finance and accounting function, implemented company-wide enterprise resource planning (ERP) and managed Big 4 audits, leading up to an IPO. Most recently, Marcel served as CFO at Mission Bio, where he was instrumental in equity financing and the negotiation of lab expansion efforts.

“We are happy to welcome Marcel as the newest member of our leadership team. With a proven track record of financial acumen and strategic thinking, Marcel will play a pivotal role in steering our financial strategies and driving growth,” said Jamie Coffin, Ph.D., CEO of NTx. “We embrace innovation in our vaccine and therapeutic manufacturing capabilities and are confident that Marcel will bring fresh perspectives and financial expertise to help us achieve our strategic goals and enhance our financial performance. Marcel is an incredible addition to the NTx team, and I look forward to working with him closely.”